Back to results
US 2006/0051381 A1Published application
Cytokine antagonists for neurological and neuropsychiatric disorders
AssigneeTact IP, LLC
InventorEdward Tobinick
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTact IP, LLC
InventorEdward Tobinick
Estimating the term…
Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, post-partum depression, and schizoaffective illness.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for delivering a TNF antagonist to a human with a neuropsychiatric disease or disorder, comprising administering said TNF antagonist parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering a TNF antagonist to a human with a neuropsychiatric disease or disorder, comprising administering said TNF antagonist by the intranasal route.
A method for delivering etanercept to a human with a neuropsychiatric disease or disorder, comprising administering said etanercept parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering D2E7 to a human with a neuropsychiatric disease or disorder, comprising administering said D2E7 parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering D2E7 to a human with Alzheimer's Disease, comprising administering said D2E7 parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering D2E7 to a human with dementia, comprising administering said D2E7 parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering infliximab to a human with a neuropsychiatric disease or disorder, comprising administering said infliximab parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering infliximab to a human with dementia, comprising administering said infliximab parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering infliximab to a human with Alzheimer's Disease, comprising administering said infliximab parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering CDP 870 to a human with a neuropsychiatric disease or disorder, comprising administering said CDP 870 parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering an interleukin-1 (IL-1) antagonist to a human with a neuropsychiatric disease or disorder, comprising administering said IL-1 antagonist parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering an interleukin-1 (IL-1) antagonist to a human with Alzheimer's Disease, comprising administering said IL-1 antagonist parenterally into the perispinal area of said human without direct intrathecal injection.
A method for delivering an interleukin-1 (IL-1) antagonist to a human with dementia, comprising administering said IL-1 antagonist parenterally into the perispinal area of said human without direct intrathecal injection.
Dependencies are inferred from the claim text.